Supreme Court Overturns Drug Calibration Patents, Creating Confusion In Biotech Realm
This article was originally published in The Pink Sheet Daily
The court’s finding that Prometheus’ drug calibration test is unpatentable has left the biotech community reeling with uncertainty as to whether method of treatment claims, particularly those involving biomarkers, will be patent eligible.
You may also be interested in...
A divided panel finds Athena Diagnostics' patent on method to diagnose myasthenia gravis is invalid; in dissent, Judge Newman cites industry concerns that the decision will deter development of new diagnostic methods.
Gilead disputed Campie FCA decision, Amgen challenged Repatha ruling, and Merck challenged "unclean hands" defense against damages. Patent and Trademark Office wants court to determine if its attorneys' fees should be covered by patent applicants challenging its decisions.
Multiple health-care stakeholders had asked the high court to take up the case of Sequenom v. Ariosa to clarify the patentability of a biotech patent. Now the Federal Circuit's interpretation that, firms say, leaves too many innovations unprotected continues to hold sway.